{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:27:55Z","timestamp":1762338475823},"reference-count":0,"publisher":"National Institute of Public Health NIH (National Research Institute)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Przegl Epidemiol"],"abstract":"<p><strong>ABSTRACT<\/strong><br \/><strong>INTRODUCTION.<\/strong> The SARS-CoV-2 pandemic has taken a heavy toll of 4 million deaths. We were all looking\u00a0forward to the authorisation of safe vaccines. Soon after vaccination programmes started, the reports about\u00a0anaphylaxis began to emerge. Growing anxiety has urged regulatory agencies and academic societies to issue\u00a0adequate recommendations regarding patient eligibility to vaccination.<br \/><strong>AIM OF THE STUDY.<\/strong> Observation of patients who had a history of a severe anaphylactic reaction and\/or\u00a0anaphylactic shock and were vaccinated against COVID-19.<br \/><strong>MATERIAL AND METHODS.<\/strong> A single-centre, prospective, observational study was conducted at the\u00a0Department of Infectious Diseases and Paediatrics at Stefan \u017beromski Specialist Hospital in Krakow, Poland.<br \/>Adult patients with a history of a severe anaphylactic reaction and\/or anaphylactic shock and patients without\u00a0it were administered the Comirnaty vaccine by Pfizer-BioNTech or the ChAdOx1-S vaccine by AstraZeneca\u00a0in a two-dose schedule at the department. The patients were then observed at the department for 60 minutes.\u00a0A week after each vaccination dose, the patients were contacted by telephone in order to collect data about a late\u00a0allergic reaction.<br \/><strong>RESULTS.<\/strong> In total, 403 patients were enrolled. For the Pfizer BioNTech Comirnaty vaccine, the study group\u00a0(i.e. patients with a history of severe anaphylactic reactions to various substances, other than those present in the\u00a0vaccine) included 151 patients, and there were 161 controls. For the AstraZeneca ChAdOx1-S vaccine, the study\u00a0group included 47 patients, and 44 patients formed the control group.<br \/>Nine cases of severe anaphylactic reactions were reported: 3 in the study groups (1.5%) and 6 in the control\u00a0groups (3%). Anaphylactic shock after vaccine administration occurred in one patient from the control group.<br \/><strong>CONCLUSIONS.<\/strong> COVID-19 vaccination with using Pfizer-BioNTech Comirnaty and AstraZeneca ChAdOx1-S\u00a0is safe also for patients with a history of a severe anaphylactic reaction and\/or anaphylactic shock. Severe\u00a0anaphylactic reactions and anaphylactic shock, although rare, may also develop in patients without a prior history\u00a0of allergic conditions. The Personnel od vaccination centres should be therefore trained to provide medical help.\u00a0Incorrect patient exclusions delay the attainment of the goal determined for the vaccination programme.<\/p>\n<p><strong>STRESZCZENIE<\/strong><br \/><strong>WST\u0118P.<\/strong> Pandemia SARS-CoV-2 poch\u0142on\u0119\u0142a ponad 4 miliony ofiar. Z niecierpliwo\u015bci\u0105 czekali\u015bmy na wprowadzenie\u00a0do u\u017cytku skutecznych szczepie\u0144 ochronnych. Wkr\u00f3tce po ich rozpocz\u0119ciu zacz\u0119\u0142y pojawia\u0107 si\u0119 raporty\u00a0przypadk\u00f3w anafilaksji. Rosn\u0105cy niepok\u00f3j zmusi\u0142 agencje regulacyjne i towarzystwa naukowe do wydania stosownych\u00a0zalece\u0144 dotycz\u0105cych kwalifikacji do szczepie\u0144.<br \/><strong>CEL PRACY.<\/strong> Obserwacje os\u00f3b szczepionych przeciwko COVID-19 obci\u0105\u017conych wywiadem ci\u0119\u017ckiej reakcji\u00a0anafilaktycznej i\/lub wstrz\u0105su anafilaktycznego.<br \/><strong>MATERIA\u0141Y I METODYKA.<\/strong> W Oddziale Chor\u00f3b Infekcyjnych i Pediatrii Szpitala Specjalistycznego\u00a0im. Stefana \u017beromskiego w Krakowie zosta\u0142o przeprowadzone jednoo\u015brodkowe, prospektywne badanie obserwacyjne.\u00a0Doros\u0142ym pacjentom z wywiadem ci\u0119\u017ckiej reakcji anafilaktycznej i\/lub wstrz\u0105su anafilaktycznego\u00a0oraz bez takiego wywiadu podano szczepionk\u0119 Pfizer-BioNTech Comirnaty lub AstraZeneca ChAdOx1-S\u00a0w schemacie dwudawkowym w warunkach oddzia\u0142u. Pacjenci byli nast\u0119pnie obserwowani w oddziale przez\u00a0okres 60 min. Po tygodniu od podania ka\u017cdej dawki szczepionki kontaktowano si\u0119 z pacjentami telefonicznie\u00a0celem zebrania wywiadu odno\u015bnie do op\u00f3\u017anionej reakcji alergicznej.<br \/><strong>WYNIKI.<\/strong> Do badania zosta\u0142o zakwalifikowanych \u0142\u0105cznie 403 pacjent\u00f3w: dla szczepionki Pfizer BioNTech\u00a0Comirnaty grupa badana (osoby z wywiadem ci\u0119\u017ckiej reakcji anafilaktycznej po r\u00f3\u017cnych substancjach, innych\u00a0ni\u017c zawarte w szczepionce) stanowi\u0142a 151 os\u00f3b oraz grupa kontrolna 161 os\u00f3b, natomiast dla szczepionki Astra-Zeneca ChAdOx1-S grupa badana 47 os\u00f3b oraz grupa kontrolna 44 osoby.<br \/>Zaraportowano 9 przypadk\u00f3w ci\u0119\u017ckich reakcji alergicznych, z czego 3 w grupach badanych (1,5%) i 6 w grupach\u00a0kontrolnych (3%). Wstrz\u0105s anafilaktyczny po podaniu szczepionki wyst\u0105pi\u0142 u jednego pacjenta w grupie\u00a0kontrolnej.<br \/><strong>WNIOSKI.<\/strong> Szczepienia przeciwko COVID-19 szczepionkami Pfizer BioNTech oraz AstraZeneca ChAdOx1-S\u00a0s\u0105 bezpieczne r\u00f3wnie\u017c dla pacjent\u00f3w z wywiadem ci\u0119\u017ckiej reakcji anafilaktycznej i\/lub wstrz\u0105su anafilaktycznego.\u00a0Ci\u0119\u017cka reakcja anafilaktyczna i wstrz\u0105s anafilaktyczny, cho\u0107 rzadkie, mog\u0105 wyst\u0105pi\u0107 r\u00f3wnie\u017c u pacjent\u00f3w\u00a0bez wcze\u015bniejszego wywiadu schorze\u0144 alergicznych, dlatego personel w punktach szczepie\u0144 powinien zosta\u0107\u00a0odpowiednio przeszkolony w zakresie udzielania pomocy medycznej. Nieprawid\u0142owe dyskwalifikacje op\u00f3\u017aniaj\u0105\u00a0osi\u0105gni\u0119cie zak\u0142adanego celu programu szczepie\u0144.<\/p><\/jats:p>","DOI":"10.32394\/pe.75.28","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T09:35:43Z","timestamp":1645090543000},"page":"315-325","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 vaccination including 198 patients with history of severe anaphylactic reaction \u2013 own observations"],"prefix":"10.32394","volume":"75","author":[{"given":"\u0141","family":"Wentrys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Stopyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17323","published-online":{"date-parts":[[2022,2,15]]},"container-title":["Przeglad Epidemiologiczny"],"original-title":["Szczepienie przeciw COVID-19 198 pacjent\u00f3w z ci\u0119\u017ck\u0105 reakcj\u0105 anafilaktyczn\u0105 w wywiadzie \u2013 obserwacje w\u0142asne"],"link":[{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/pdf-181012-101572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/pdf-181012-101572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T08:44:43Z","timestamp":1709887483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.przeglepidemiol.pzh.gov.pl\/COVID-19-vaccination-including-198-patients-with-history-of-severe-anaphylactic-reaction,181012,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"alternative-id":["181012"],"URL":"https:\/\/doi.org\/10.32394\/pe.75.28","relation":{},"ISSN":["0033-2100","2545-1898"],"issn-type":[{"value":"0033-2100","type":"print"},{"value":"2545-1898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}